Serum free IGF-I during a hyperinsulinemic clamp following 3 days of administration of IGF-I vs. saline

J. Frystyk, Mehboob Hussain, C. Skjærbæk, O. Schmitz, J. S. Christiansen, E. R. Froesch, H. Ørskov

Research output: Contribution to journalArticle

Abstract

In a randomized crossover study in eight healthy subjects, we compared the effect of 3 days of continuous subcutaneous administration of insulin- like growth factor I (IGF-I; 10 μg · kg-1 · h-1) and saline of fasting serum levels of free IGF-I, total (extractable) IGF-I, and IGF-binding protein (IGFBP)-1 and -3. On the 3rd day a hyperinsulinemic (euglycemic and hypoglycemic) clamp was performed. When preclamp (baseline) levels were compared after 3 days, IGF-I administration had increased total IGF-I from 225 ± 21 (means ± SE) to 1,003 ± 46 μg/l (P <0.0001), free IGF-I from 0.5 ± 0.2 to 10.4 ± 1.7 μg/l (P <0.001), IGFBP-3 from 2,908 ± 148 to 3,591 ± 179 μg/l (P <0.01), and IGFBP-I from 7.6 ± 3.8 to 19.6 ± 2.5 μg/l (P <0.01). During the clamp, levels of free IGF-I increased gradually from baseline to 1.0 ± 0.3 μg/l (saline; P <0.01) and to 19.6 ± 4.7 μg/l (IGF-I; P <0.005). Concomitantly, levels of IGFBP-1 decreased gradually from baseline to 4.1 ± 2.3 μg/l (saline; P <0.0005) and to 4.6 ± 1.8 μg/l (IGF-I; P <0.0001). Total IGF-I exhibited minor changes only during the clamp (P <0.05), and the IGFBP-3 was unchanged. In conclusion, administration of IGF-I increased total IGF-I about fourfold, whereas free IGF-I increased 20-fold. Noteworthily, in both situations a further twofold increase in free IGF-I was observed during the hyperinsulinemic clamp, concomitant with a decrease in IGFBP-1. This supports the hypothesis that IGFBP-1 is important in the short-term regulation of free IGF-I in vivo.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume273
Issue number3 36-3
StatePublished - Sep 1997
Externally publishedYes

Fingerprint

Clamping devices
Insulin-Like Growth Factor I
Serum
Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor Binding Protein 2
Insulin-Like Growth Factor Binding Proteins
Glucose Clamp Technique
Hypoglycemic Agents
Cross-Over Studies

Keywords

  • Insulin-like growth factor I
  • Insulin-like growth factor- binding protein-1
  • Insulin-like growth factor-binding protein-3
  • Recombinant human insulin-like growth factor I
  • Ultrafiltration

ASJC Scopus subject areas

  • Physiology
  • Endocrinology
  • Biochemistry

Cite this

Frystyk, J., Hussain, M., Skjærbæk, C., Schmitz, O., Christiansen, J. S., Froesch, E. R., & Ørskov, H. (1997). Serum free IGF-I during a hyperinsulinemic clamp following 3 days of administration of IGF-I vs. saline. American Journal of Physiology - Endocrinology and Metabolism, 273(3 36-3).

Serum free IGF-I during a hyperinsulinemic clamp following 3 days of administration of IGF-I vs. saline. / Frystyk, J.; Hussain, Mehboob; Skjærbæk, C.; Schmitz, O.; Christiansen, J. S.; Froesch, E. R.; Ørskov, H.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 273, No. 3 36-3, 09.1997.

Research output: Contribution to journalArticle

Frystyk, J. ; Hussain, Mehboob ; Skjærbæk, C. ; Schmitz, O. ; Christiansen, J. S. ; Froesch, E. R. ; Ørskov, H. / Serum free IGF-I during a hyperinsulinemic clamp following 3 days of administration of IGF-I vs. saline. In: American Journal of Physiology - Endocrinology and Metabolism. 1997 ; Vol. 273, No. 3 36-3.
@article{9ac901f233d945a4bc286c9de7972c90,
title = "Serum free IGF-I during a hyperinsulinemic clamp following 3 days of administration of IGF-I vs. saline",
abstract = "In a randomized crossover study in eight healthy subjects, we compared the effect of 3 days of continuous subcutaneous administration of insulin- like growth factor I (IGF-I; 10 μg · kg-1 · h-1) and saline of fasting serum levels of free IGF-I, total (extractable) IGF-I, and IGF-binding protein (IGFBP)-1 and -3. On the 3rd day a hyperinsulinemic (euglycemic and hypoglycemic) clamp was performed. When preclamp (baseline) levels were compared after 3 days, IGF-I administration had increased total IGF-I from 225 ± 21 (means ± SE) to 1,003 ± 46 μg/l (P <0.0001), free IGF-I from 0.5 ± 0.2 to 10.4 ± 1.7 μg/l (P <0.001), IGFBP-3 from 2,908 ± 148 to 3,591 ± 179 μg/l (P <0.01), and IGFBP-I from 7.6 ± 3.8 to 19.6 ± 2.5 μg/l (P <0.01). During the clamp, levels of free IGF-I increased gradually from baseline to 1.0 ± 0.3 μg/l (saline; P <0.01) and to 19.6 ± 4.7 μg/l (IGF-I; P <0.005). Concomitantly, levels of IGFBP-1 decreased gradually from baseline to 4.1 ± 2.3 μg/l (saline; P <0.0005) and to 4.6 ± 1.8 μg/l (IGF-I; P <0.0001). Total IGF-I exhibited minor changes only during the clamp (P <0.05), and the IGFBP-3 was unchanged. In conclusion, administration of IGF-I increased total IGF-I about fourfold, whereas free IGF-I increased 20-fold. Noteworthily, in both situations a further twofold increase in free IGF-I was observed during the hyperinsulinemic clamp, concomitant with a decrease in IGFBP-1. This supports the hypothesis that IGFBP-1 is important in the short-term regulation of free IGF-I in vivo.",
keywords = "Insulin-like growth factor I, Insulin-like growth factor- binding protein-1, Insulin-like growth factor-binding protein-3, Recombinant human insulin-like growth factor I, Ultrafiltration",
author = "J. Frystyk and Mehboob Hussain and C. Skj{\ae}rb{\ae}k and O. Schmitz and Christiansen, {J. S.} and Froesch, {E. R.} and H. {\O}rskov",
year = "1997",
month = "9",
language = "English (US)",
volume = "273",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "3 36-3",

}

TY - JOUR

T1 - Serum free IGF-I during a hyperinsulinemic clamp following 3 days of administration of IGF-I vs. saline

AU - Frystyk, J.

AU - Hussain, Mehboob

AU - Skjærbæk, C.

AU - Schmitz, O.

AU - Christiansen, J. S.

AU - Froesch, E. R.

AU - Ørskov, H.

PY - 1997/9

Y1 - 1997/9

N2 - In a randomized crossover study in eight healthy subjects, we compared the effect of 3 days of continuous subcutaneous administration of insulin- like growth factor I (IGF-I; 10 μg · kg-1 · h-1) and saline of fasting serum levels of free IGF-I, total (extractable) IGF-I, and IGF-binding protein (IGFBP)-1 and -3. On the 3rd day a hyperinsulinemic (euglycemic and hypoglycemic) clamp was performed. When preclamp (baseline) levels were compared after 3 days, IGF-I administration had increased total IGF-I from 225 ± 21 (means ± SE) to 1,003 ± 46 μg/l (P <0.0001), free IGF-I from 0.5 ± 0.2 to 10.4 ± 1.7 μg/l (P <0.001), IGFBP-3 from 2,908 ± 148 to 3,591 ± 179 μg/l (P <0.01), and IGFBP-I from 7.6 ± 3.8 to 19.6 ± 2.5 μg/l (P <0.01). During the clamp, levels of free IGF-I increased gradually from baseline to 1.0 ± 0.3 μg/l (saline; P <0.01) and to 19.6 ± 4.7 μg/l (IGF-I; P <0.005). Concomitantly, levels of IGFBP-1 decreased gradually from baseline to 4.1 ± 2.3 μg/l (saline; P <0.0005) and to 4.6 ± 1.8 μg/l (IGF-I; P <0.0001). Total IGF-I exhibited minor changes only during the clamp (P <0.05), and the IGFBP-3 was unchanged. In conclusion, administration of IGF-I increased total IGF-I about fourfold, whereas free IGF-I increased 20-fold. Noteworthily, in both situations a further twofold increase in free IGF-I was observed during the hyperinsulinemic clamp, concomitant with a decrease in IGFBP-1. This supports the hypothesis that IGFBP-1 is important in the short-term regulation of free IGF-I in vivo.

AB - In a randomized crossover study in eight healthy subjects, we compared the effect of 3 days of continuous subcutaneous administration of insulin- like growth factor I (IGF-I; 10 μg · kg-1 · h-1) and saline of fasting serum levels of free IGF-I, total (extractable) IGF-I, and IGF-binding protein (IGFBP)-1 and -3. On the 3rd day a hyperinsulinemic (euglycemic and hypoglycemic) clamp was performed. When preclamp (baseline) levels were compared after 3 days, IGF-I administration had increased total IGF-I from 225 ± 21 (means ± SE) to 1,003 ± 46 μg/l (P <0.0001), free IGF-I from 0.5 ± 0.2 to 10.4 ± 1.7 μg/l (P <0.001), IGFBP-3 from 2,908 ± 148 to 3,591 ± 179 μg/l (P <0.01), and IGFBP-I from 7.6 ± 3.8 to 19.6 ± 2.5 μg/l (P <0.01). During the clamp, levels of free IGF-I increased gradually from baseline to 1.0 ± 0.3 μg/l (saline; P <0.01) and to 19.6 ± 4.7 μg/l (IGF-I; P <0.005). Concomitantly, levels of IGFBP-1 decreased gradually from baseline to 4.1 ± 2.3 μg/l (saline; P <0.0005) and to 4.6 ± 1.8 μg/l (IGF-I; P <0.0001). Total IGF-I exhibited minor changes only during the clamp (P <0.05), and the IGFBP-3 was unchanged. In conclusion, administration of IGF-I increased total IGF-I about fourfold, whereas free IGF-I increased 20-fold. Noteworthily, in both situations a further twofold increase in free IGF-I was observed during the hyperinsulinemic clamp, concomitant with a decrease in IGFBP-1. This supports the hypothesis that IGFBP-1 is important in the short-term regulation of free IGF-I in vivo.

KW - Insulin-like growth factor I

KW - Insulin-like growth factor- binding protein-1

KW - Insulin-like growth factor-binding protein-3

KW - Recombinant human insulin-like growth factor I

KW - Ultrafiltration

UR - http://www.scopus.com/inward/record.url?scp=0030774836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030774836&partnerID=8YFLogxK

M3 - Article

VL - 273

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 3 36-3

ER -